Abstract
This chapter is dedicated to Gustav Hör, Professor Emeritus and former Director of the Department of Nuclear Medicine, University of Frankfurt/Main, on the occasion of his 75th birthday.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G (1998) Limited value of fluorine-18 fluo-rodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25:79–83
Ahlstrom H, Eriksson B, Bergstrom M, Bjurling P, Lang-strom B, Oberg K (1995) Pancreatic neuroendocrinetumors: diagnosis with PET. Radiology 195:333–337
Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW (2001) 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 42:213–221
Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H (2007) Are radiogallium-labelled DOTA-conjugated somatostatin superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34:982–993
Baum RP, Hofmann M (2004) Nuklearmedizinische Diagnostik neuroendocriner tumoren. Onkologe 10:598–610
Baum RP, Prasad V (2007) Molecular imaging of neuro-endocrine tumors using Ga-68 DOTA-NOC receptor PET/CT semiquantitative analyses after 1,257 studies (EPOS). European Congress of Radiology 2007, Vienna, Austria
Baylin SB, Abeloff MD, Goodwin G, Carney DN, Gazdar AF (1980) Activities of L-dopa decarboxylase and diamine oxidase (histaminase) in human lung cancers and decarboxylase as a marker for small (oat) cell cancer in cell culture. Cancer Res 40:1990–1994
Becherer A, Szabo M, Karanikas G, Wunderbaidinger P, Angelberger P, Raderer M, Kurtaran A, Dudczak R, Kletter K (2004) Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 45:1161–1167
Behe M, Becker W, Gotthardt M, Angerstein C, Behr TM (2003) Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled mini-gastrin derivatives. Eur J Nucl Med Mol Imaging 30:1140–1146
Behr TM, Behe MP (2002) Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystoki-nin-B receptor-expressing malignancies. Semin Nucl Med 32:97–109
Behr TM, Jenner N, Radetzky S, Behe M, Gratz S, Yucekent S, Raue F, Becker W (1998) Targeting of chole-cystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 25:424–430
Behr TM, Behe M, Angerstein C, Gratz S, Mach R, Hagemann L, Jenner N, Stiehler M, Frank-Raue K, Raue F, Becker W (1999) Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 5:3124s–3138s
Behr TM, Gotthardt M, Barth A, Behe M (2001) Imaging tumors with peptide-based radioligands. Q J Nucl Med 45:189–200
Berger CL, de Bustros A, Roos BA, Leong SS, Mendelsohn G, Gesell MS, Baylin SB (1984) Human medullary thyroid carcinoma in culture provides a model relating growth dynamics, endocrine cell differentiation, and tumor progression. J Clin Endocrinol Metab 59:338–343
Berglund AS, Hulthen UL, Manhem P, Thorsson O, Wollmer P, Tornquist C (2001) Metaiodobenzylgua-nidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomas. J Intern Med 249:247–251
Blum J, Handmaker H, Lister-James J, Rinne N (2000) A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 117:1232–1238
Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A (2001) Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 12 [Suppl 2]:S51–S61
Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E (2004) Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging 48:150–163
Breeman WA, De Jong M, Bernard BF, Kwekkeboom DJ, Srinivasan A, van der Pluijm ME, Hofland LJ, Visser TJ, Krenning EP (1999) Pre-clinical evaluation of [(111)In-DTPA-Pro(l), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 83:657–663
Castellani MR, Chiti A, Seregni E, Bombardieri E (2000) Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med 44:77–87
De Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, Visser TJ, Jermann E, Behe M, Powell P, Macke HR (1997) Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 24:368–371
Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ (2000) 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 41:1114–1119
Deutsch E (1993) Clinical PET: its time has come? J Nucl Med 34:1132–1133
Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grunwald F (2001) Fluorine-18 fluorode-oxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28:1671–1676
Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K, Langstrom B (2000) Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med 44:68–76
Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila RI, Mulshine JL, Schuller HM, Park JG (1988) Expression of neuroendocrine cell markers L-dopa decar-boxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 48:4078–4082
Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR (2005) Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 11:1136–1145
Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Macke HR, Reubi JC (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sei USA 103:16436–16441
Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, Macke HR, Hofmann M, Debus J, Haberkorn U (2001) PET imaging of somatostatin receptors using [68GA]DOTA-D-Phel-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 42:1053–1056
Henze M, Schuhmacher J, Dimitrakopoulou-Strauss A, Strauss LG, Macke HR, Eisenhut M, Haberkorn U (2004) Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET. Eur J Nucl Med Mol Imaging 31:466
Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, Macke HR, Eisenhut M, Debus J, Haberkorn U (2005) Characterization of Ga-DOTA-D-Phe1Tyr33-octreotide kinetics in patients with meningiomas. J Nucl Med 46:763–769
Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HP (2002) Pheochromocytomas: detection with 18F DOPA whole body PET: initial results. Radiology 222:507–512
Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751–1757
Jacob T, Grahek D, Younsi N, Kerrou K, Aide N, Montravers F, Balogova S, Colombet C, De Beco V, Talbot JN (2003) Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results. Eur J Nucl Med Mol Imaging 30:1266–1269
Jensen RT (2005) Endocrine tumors of the gastrointestinal tract and pancreas. In: Kasper DL, Fauci AS, Longo DL et al. (eds) Harrison’s principles of internal medicine. McGraw-Hill, New York, pp 2221–2231
Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuro-endocrine tumors. Endocr Rev 25:458–511
Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC (1989) Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 30:481–489
Koukouraki S, Strauss L, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A (2006) Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neu-roendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33:460–466
Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U (2003) Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [nlIn]-DTPAOC SPECT. First results in patients with neu-roendocrine tumors. Mol Imaging Biol 5:42–48
Krenning EP, Bakker WH, Breeman WA, Köper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1:242–244
Krenning EP, Bakker WH, Lamberts SW (1990) Receptor scintigraphy with somatostatin analog in oncology. Ned Tijdschr Geneeskd 134:1077–1080
Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ et al (1992) Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-l-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 33:652–658
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC et al (1993) Somatostatin receptor scin-tigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731
Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M (2004) Peptide receptor radio-nuclide therapy. Ann N Y Acad Sci 1014:234–245
Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue JA, Krenning EP (1994) The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 21:1106–1113
Kwekkeboom DJ, Bakker WH, Kooij PP, Erion J, Srinivasan A, de Jong M, Reubi JC, Krenning EP (2000) Cholecystokinin receptor imaging using an octapep-tide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 27:1312–1317
Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP (2001) [177Lu-DOTAOTyr3]octreotate: comparison with [mIn-DTPAo]octreotide in patients. Eur J Nucl Med 28:1319–1325
Lebtahi R, Le Cloirec J, Houzard C, Daou D, Sobhani I, Sassolas G, Mignon M, Bourguet P, Le Guludec D (2002) Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with lllln-pentetreo-tide scintigraphy. J Nucl Med 43:889–895
Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, Morris MM, Miller JP, Anderson CJ (1999) Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res 5:3608–3616
Li S, Beheshti M (2005) The radionuclide molecular imaging and therapy of neuroendocrine tumors. Curr Cancer Drug Targets 5:139–148
Maecke HR, Hofmann M, Haberkorn U (2005) (68)Ga-labeled peptides in tumor imaging. J Nucl Med 46 [Suppl 1]:172S–178S
Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, Herz M, Wester HJ, Schwaiger M (2006) Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [mIn]DTPA-octreo-tide. J Nucl Med 47:566–573
Moody TW, Hill JM, Jensen RT (2003) VIP as a trophic factor in the CNS and cancer cells. Peptides 24:163–177
Oberndorfer S (1907) Karzinoide tumoren des dünndarms. Frankf Z Pathol 1:426–429
Ohta H, Yamamoto K, Endo K, Mori T, Hamanaka D, Shimazu A, Ikekubo K, Makimoto K, Iida Y, Konishi J et al (1984) A new imaging agent for medullary carcinoma of the thyroid. J Nucl Med 25:323–325
Orlefors H, Sundin A, Ahlstrom H, Bjurling P, Bergstrom M, Lilja A, Langstrom B, Oberg K, Eriksson B (1998) Positron emission tomography with 5-hydroxytry-prophan in neuroendocrine tumors. J Clin Oncol 16:2534–2541
Otte A, Mueller-Brand J, Delias S, Nitzsche EU, Herrmann R, Maecke HR (1998) Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351:417–478
Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Müller J (1999) Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26:1439–1447
Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Braud F (2001) Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreo-tide. Eur J Nucl Med 28:426–434
Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, Ferlin G, Pedrazzoli S (1998) Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22:588–592
Pasquali C, Sperti C, Scappin S, Lunardi C, Chierichetti F, Liessi G, Pedrazzoli S (2004) Role and indications of fluorodeoxyglucose positron emission tomography (FDG-PET) in neuroendocrine pancreatico-duode-nal tumors. J Pancreas 6 [5 Suppl]:528–529
Pearse AG (1969) The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologie, physiologic and pathologic implications of the concept. J Histochem Cytochem 17:303–313
Pershagen G (1998) Environmental epidemiology in public health. Lancet 352:417
Raderer M, Pangerl T, Leimer M, Valencak J, Kurtaran A, Hamilton G, Scheithauer W, Virgolini I (1998) Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo. J Natl Cancer Inst 90:1666–1668
Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781–793
Reubi JC, Schaer JC, Waser B (1997) Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 57:1377–1386
Reubi JC, Waser B, Schaer JC, Laederach U, Erion J, Srinivasan A, Schmidt MA, Bugaj JE (1998) Unsul-fated DTPA-and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 25:481–490
Reubi JC, Gugger M, Waser B, Schaer JC (2001a) Y(l)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 61:4636–4641
Reubi JC, Waser B, Schaer JC, Laissue JA (2001b) Somatostatin receptor sstl-sst5 expression in normal and neoplastic human tissues using receptor autoradiog-raphy with subtype-selective ligands. Eur J Nucl Med 28:836–846
Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA (2000a) Vasoactive intestinal peptide/ pituitary adenylate cydase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 60:3105–3112
Reubi JC, Schaer JC, Wenger S, Hoeger C, Erchegyi J, Waser B, Rivier J (2000b) SST3-selective potent pep-tidic somatostatin receptor antagonists. Proc Natl Acad Sci USA 97:13973–3978
Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR (2000c) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273–282
Reubi C, Gugger M, Waser B (2002) Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 29:855–862
Rufini V, Calcagni ML, Baum RP (2006) Imaging of neuroendocrine tumors. Semin Nucl Med 36:228–247
Scanga DR, Martin WH, Delbeke D (2004) Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med 29:86–90
Schmitt-Gräff A, Hezel B, Wiedenmann B (2000) Pathologisch-diagnostische Aspekte neuroendokriner tumoren des Gastrointestinal trakts. Onkologe 6:613–623
Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26:576–585
Shapiro B, Fig LM, Gross MD, Khafagi F (1989) Radio-chemical diagnosis of adrenal disease. Crit Rev Clin Lab Sci 27:265–298
Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE (1992) A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13:513–521
Solcia E, Klöppel G, Sobin LH (2000) Histological typing of tumors. International Histological Classification of Tumors in collaboration with 9 pathologists from 4 countries (WH OP PW H. Organisation, ed.) Springer, Berlin New York Heidelberg
Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C (1998) The somatostatin receptor-targeted radiotherapeutic [ Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 25:668–674
Sundin A, Eriksson B, Bergstrom M, Langstrom B, Oberg K, Orlefors H (2004) PET in the diagnosis of neuroen-docrine tumors. Ann NY Acad Sci 1014:246–257
Takekawa H, Shinano H, Tsukamoto E, Koseki Y, Ikeno T, Miller F, Kawakami Y (1999) Technetium-99m-tet-rofosmin imaging of lung cancer: relationship with histopathology. Ann Nucl Med 13:71–75
Thakur ML, Marcus CS, Saeed S, Pallela V, Minami C, Diggles L, Le Pham H, Ahdoot R, Kalinowski EA (2000) 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med 41:107–110
Van Hagen PM, Breeman WA, Reubi JC, Postema PT, van den Anker-Lugtenburg PJ, Kwekkeboom DJ, Laissue J, Waser B, Lamberts SW, Visser TJ, Krenning EP (1996) Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 23:1508–1513
Virgolini I (2000) Peptide imaging. Springer, Berlin New York Heidelberg
Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W, Valent P (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N EnglJ Med 331:1116–1121
Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, Li S, Scheithauer W, Niederle B, Valent P et al (1995) Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 36:1732–1739
Virgolini I, Raderer M, Kurtaran A, Angelberger P, Yang Q, Radosavljevic M, Leimer M, Kaserer K, Li SR, Kornek G, Hübsch P, Niederle B, Pidlich J, Scheithauer W, Valent P (1996) 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 23:685–692
Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Vorbeck F, Bischof C, Leimer M, Dorner G, Kletter K, Niederle B, Scheithauer W, Smith-Jones P (1998) Indium-lll-DOTA-lanreotide: biodistribu-tion, safety and radiation absorbed dose in tumor patients. J Nucl Med 39:1928–1936
Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J (2002) Tumor response and clinical benefit in neu-roendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43:610–616
Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ (2003) Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res 63:6864–6869
Weiner RE, Thakur ML (2002) Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 57:749–763
Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2:3 and 5 for labelling with various radio-metals. Eur J Nucl Med Mol Imaging 30:1338–1347
Zhao DS, Valdivia AY, Li Y, Blaufox MD (2002) 18F-fluo-rodeoxyglucose positron emission tomography in small-cell lung cancer. Semin Nucl Med 32:272–275
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Baum, R.P., Prasad, V., Hommann, M., Hörsch, D. (2008). Receptor PET/CT Imaging of Neuroendocrine Tumors. In: Dresel, S. (eds) PET in Oncology. Recent Results in Cancer Research, vol 170. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-31203-1_18
Download citation
DOI: https://doi.org/10.1007/978-3-540-31203-1_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-31202-4
Online ISBN: 978-3-540-31203-1
eBook Packages: MedicineMedicine (R0)